Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST)

Table 1 Enrolment, interventions and assessments in the FORECAST study

	Patient identification	Before randomization	Study treatment (5–8 days)	6–10 days post-end of treatment	30–35 days post-end of treatment
Enrolment:
Screening for eligibility	x
Entry criteria		x
Informed consent		x
Interventions:
Venapunction^a		x
Urine/blood culture	x			x (urine)
Study treatment			x
Assessments:
Electronic patient file		x		x	x
Patient questionnaire		x		x	x
Hand in study diary and residual study medicines				x

^ain case of doubt about the following exclusion criteria: pregnancy, neutropenia or renal insufficiency

ISSN: 1471-2334